These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 34590082)

  • 1. Updates in fatty liver disease: Pathophysiology, diagnosis and management.
    Gofton C; George J
    Aust J Gen Pract; 2021 Oct; 50(10):702-707. PubMed ID: 34590082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
    Tang SY; Tan JS; Pang XZ; Lee GH
    World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention.
    Zhou XD; Cai J; Targher G; Byrne CD; Shapiro MD; Sung KC; Somers VK; Chahal CAA; George J; Chen LL; Zhou Y; Zheng MH;
    Cardiovasc Diabetol; 2022 Dec; 21(1):270. PubMed ID: 36463192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of MAFLD and NAFLD diagnostic criteria in real world.
    Lin S; Huang J; Wang M; Kumar R; Liu Y; Liu S; Wu Y; Wang X; Zhu Y
    Liver Int; 2020 Sep; 40(9):2082-2089. PubMed ID: 32478487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updates in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Children.
    Rupasinghe K; Hind J; Hegarty R
    J Pediatr Gastroenterol Nutr; 2023 Nov; 77(5):583-591. PubMed ID: 37592398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A problem of proportions: estimates of metabolic associated fatty liver disease and liver fibrosis in Australian adults in the nationwide 2012 AusDiab Study.
    Farrell AM; Magliano DJ; Shaw JE; Thompson AJ; Croagh C; Ryan MC; Howell J
    Sci Rep; 2022 Feb; 12(1):1956. PubMed ID: 35121749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.
    Chan WK; Tan SS; Chan SP; Lee YY; Tee HP; Mahadeva S; Goh KL; Ramli AS; Mustapha F; Kosai NR; Raja Ali RA
    J Gastroenterol Hepatol; 2022 May; 37(5):795-811. PubMed ID: 35080048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAFLD: How is it different from NAFLD?
    Gofton C; Upendran Y; Zheng MH; George J
    Clin Mol Hepatol; 2023 Feb; 29(Suppl):S17-S31. PubMed ID: 36443926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Metabolic-Associated Fatty Liver Disease.
    Venkatesan K; Haroon NN
    Endocrinol Metab Clin North Am; 2023 Sep; 52(3):547-557. PubMed ID: 37495344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study.
    Baratta F; Ferro D; Pastori D; Colantoni A; Cocomello N; Coronati M; Angelico F; Del Ben M
    Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic Dysfunction-Associated Fatty Liver Disease Is Associated with the Risk of Incident Cardiovascular Disease: A Prospective Cohort Study in Xinjiang.
    Guo Y; Yang J; Ma R; Zhang X; Guo H; He J; Wang X; Cao B; Maimaitijiang R; Li Y; Peng X; Zhang S; Guo S
    Nutrients; 2022 Jun; 14(12):. PubMed ID: 35745091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD.
    Nguyen VH; Le MH; Cheung RC; Nguyen MH
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2172-2181.e6. PubMed ID: 34033923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
    Liu D; Shen Y; Zhang R; Xun J; Wang J; Liu L; Steinhart C; Chen J; Lu H
    J Gastroenterol Hepatol; 2021 Jun; 36(6):1670-1678. PubMed ID: 33140878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives.
    Vimalesvaran S; Vajro P; Dhawan A
    Hepatol Int; 2024 Oct; 18(Suppl 2):873-883. PubMed ID: 38879851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?
    Kjær MB; George J; Kazankov K; Grønbæk H
    Expert Rev Gastroenterol Hepatol; 2021 Jan; 15(1):51-64. PubMed ID: 32878486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic-Associated Fatty Liver Disease: A Disastrous Human Health Challenge.
    Fouda S; Pappachan JM
    Endocrinol Metab Clin North Am; 2023 Sep; 52(3):xv-xvi. PubMed ID: 37495346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
    Guerreiro GTS; Longo L; Fonseca MA; de Souza VEG; Álvares-da-Silva MR
    Hepatol Int; 2021 Apr; 15(2):380-391. PubMed ID: 33694066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study.
    Niriella MA; Ediriweera DS; Kasturiratne A; De Silva ST; Dassanayaka AS; De Silva AP; Kato N; Pathmeswaran A; Wickramasinghe AR; de Silva HJ
    PLoS One; 2021; 16(2):e0245762. PubMed ID: 33534815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lean Metabolic-Associated Fatty Liver Disease.
    Gofton C; Clark-Dickson M; George J
    Endocrinol Metab Clin North Am; 2023 Sep; 52(3):431-444. PubMed ID: 37495335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.
    Lee H; Lee YH; Kim SU; Kim HC
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2138-2147.e10. PubMed ID: 33348045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.